| Phase 12 trials |
|
Phase 1
|
NCT03023787 |
Aug → Dec 2016 |
chronic hepatitis B virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02612506 |
Oct 2015 → Aug 2016 |
chronic hepatitis B virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT06505928 |
Dec 2024 → May 2026 overdue |
hepatitis D virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05827146 |
Oct 2023 → Jan 2024 |
hepatitis D virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05244057 |
Aug 2022 → Jun 2024 |
chronic hepatitis B virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04426968 |
Jun 2021 → Nov 2023 |
chronic hepatitis B virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07309380 |
Apr 2026 → Jun 2027 expected |
hepatitis D virus infection |
Shanghai HEP Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|